Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-19

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational post-market clinical Follow-up study is to learn about the long-term safety, performance, and clinical benefits of pacing the left bundle branch area (LBBAP) using the INGEVITY+ pacemaker lead in patients with bradycardia who need a pacemaker.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bradycardia Atrioventricular Block Sinus Node Dysfunction Bundle-Branch Block

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Left Bundle Branch Area Pacing (LBBAP) INGEVITY+ Lead Pacemaker Cardiac Pacing Conduction System Pacing Ventricular Synchrony Post-Market Clinical Follow-up

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients receiving INGEVITY+ lead for left bundle branch area pacing

This group includes adult patients with bradycardia who are indicated for a Boston Scientific pacemaker system. All participants will undergo implantation of an INGEVITY+ pace/sense lead in the left bundle branch area (LBBAP) with a compatible Boston Scientific pacemaker.

Pacemaker lead

Intervention Type DEVICE

The pacemaker lead under investigation is a bipolar, steroid-releasing pacemaker electrode with active fixation (IS-1 connection) designed for chronic stimulation and sensing in the right atrium, right ventricle or left bundle branch area (LBBA). In this study, the lead is implanted in the LBBA and connected to a single- or dual-chamber pacemaker. Implantation is performed using a compatible, CE-marked catheter for pacemaker implantation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pacemaker lead

The pacemaker lead under investigation is a bipolar, steroid-releasing pacemaker electrode with active fixation (IS-1 connection) designed for chronic stimulation and sensing in the right atrium, right ventricle or left bundle branch area (LBBA). In this study, the lead is implanted in the LBBA and connected to a single- or dual-chamber pacemaker. Implantation is performed using a compatible, CE-marked catheter for pacemaker implantation.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Bradycardia pacemaker system Left Bundle Branch Area Pacing (LBBAP) Lead

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects intended to undergo initial (de novo) pacing system implant using the INGEVITY+ lead in the left bundle branch area (LBBA) and a Boston Scientific single or dual- chamber pacemaker (Note: no prior attempted pacing system components);
2. Subjects who are indicated for and will receive a Boston Scientific pacemaker system (including the single or dual chamber pacemaker and an INGEVITY+ lead in the LBBA location) for one of the following medical conditions:

1. Symptomatic paroxysmal or permanent second- or third-degree AV block,
2. Symptomatic bilateral bundle branch block,
3. Symptomatic paroxysmal or transient sinus node dysfunction with or without associated AV conduction disorders (i.e., sinus bradycardia, sinus arrest, sinoatrial \[SA\] block),
4. Bradycardia-tachycardia syndrome, to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias,
5. Neurovascular (vasovagal) syndromes or hypersensitive carotid sinus syndromes,
6. Adaptive-rate pacing for patients exhibiting chronotropic incompetence and who may benefit from increased pacing rates concurrent with increases in minute ventilation and/or level of physical activity.

Dual-chamber and atrial tracking modes are also indicated for patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of the following:
7. Conduction disorders that require restoration of AV synchrony, including varying degrees of AV block,
8. VVI intolerance (i.e., pacemaker syndrome) in the presence of persistent sinus rhythm,
9. Low cardiac output or congestive heart failure secondary to bradycardia;
3. Subjects willing and capable of providing informed consent and participating in all testing and clinic visits associated with the clinical study at an approved clinical study location and at the intervals defined by protocol;
4. Subjects who are ≥18 years of age, and of legal age to give informed consent specific to state and national law.

Exclusion Criteria

1. Subjects meeting guideline indications for cardiac resynchronization therapy (CRT) in the absence of a bradycardia indication;
2. Subjects with a known or suspected sensitivity to dexamethasone acetate (DXA);
3. Subjects with a Mechanical Tricuspid Valve;
4. Subjects requiring hemodialysis or peritoneal dialysis;
5. Subject has or has had implanted any pacemaker, ICD system, including subcutaneous, transvenous or leadless systems (Note: except for temporary pacing wire at time of enrollment) or CRT system;
6. Subjects currently on an active organ transplant list;
7. Subject referred to or admitted for hospice care;
8. Subjects with a documented life expectancy of less than 12 months;
9. Subjects enrolled in any other concurrent study (unless prior approval is received from the Sponsor);
10. Subjects who are, or plan to become pregnant during the course of the study or are breastfeeding at time of enrollment;
11. Subjects who are unable or unwilling to comply with the follow-up schedule, including those living at such a distance from the investigational site that attending follow-up visits would be unusually difficult or burdensome.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Aurélien Wauters, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Clinique St-Pierre Ottignies

Locations

Explore where the study is taking place and check the recruitment status at each participating site.